| Literature DB >> 28446863 |
Frederick Verbeke1, Severine De Craemer1, Nathan Debunne1, Yorick Janssens1, Evelien Wynendaele1, Christophe Van de Wiele2,3, Bart De Spiegeleer1.
Abstract
The expression of certain bacterial genes is regulated in a cell-density dependent way, a phenomenon called quorum sensing. Both Gram-negative and Gram-positive bacteria use this type of communication, though the signal molecules (auto-inducers) used by them differ between both groups: Gram-negative bacteria use predominantly N-acyl homoserine lacton (AHL) molecules (autoinducer-1, AI-1) while Gram-positive bacteria use mainly peptides (autoinducer peptides, AIP or quorum sensing peptides). These quorum sensing molecules are not only involved in the inter-microbial communication, but can also possibly cross-talk directly or indirectly with their host. This review summarizes the currently applied analytical approaches for quorum sensing identification and quantification with additionally summarizing the experimentally found in vivo concentrations of these molecules in humans.Entities:
Keywords: analytical methods; biosensors; chromatography; microbiome; quorum sensing peptides; reporter bacteria
Year: 2017 PMID: 28446863 PMCID: PMC5388746 DOI: 10.3389/fnins.2017.00183
Source DB: PubMed Journal: Front Neurosci ISSN: 1662-453X Impact factor: 4.677
Figure 1(Left panel) Typical Gram-negative quorum sensing mechanism. Acyl homoserine lactone molecules, synthesized by LuxI, passively pass the bacterial cell membrane and when a sufficient concentration is reached (threshold level) activate the intracellular LuxR which subsequently activates target gene expression in a coordinated way. (Right panel) Quorum sensing peptides are synthesized by the bacterial ribosomes as pro-peptidic proteins and undergo posttranslational modifications during excretion by active transport. The quorum sensing peptides bind membrane associated receptors which get autophosphorylated and activate intracellular response regulators via phosphor-transfer. These phosphorylated response regulators induce increased target gene expression.
Figure 2Various quorum sensing peptides, illustrating the structural diversity observed among quorum sensing peptide.
Figure 3(Left panel) A quorum sensing reporter strain based on genetic modification: bacteria are genetically modified to make them competent to detect the specific quorum sensing peptide. Upon addition of a sample containing the quorum sensing peptide, the activated quorum sensing peptide receptor triggers in this example bioluminescence, allowing detection and quantification of the quorum sensing peptide (La Rosa et al., 2015). (Right panel) A quorum sensing reporter strain based on the naturally observed quorum sensing mechanism of a quorum sensing peptide (in this example the clumping induction assay as observed with various E. faecalis quorum sensing peptides Suzuki et al., 1984; Mori et al., 1988; Nakayama et al., 1995a). A sample containing the quorum sensing peptide is added to a bacterial strain capable of detecting the quorum sensing peptide and the formation of clumps is observed via light scattering.
Overview of some plasmid-based AHL reporter strains (Steindler and Venturi, .
| pSB401 | 3-oxo-C4- to 3-oxo-C14-HSL C4- to C12-HSL | |||
| pSB1075 | 3-oxo-C12- to 3-oxo-C16-HSL C12- to C16-HSL | |||
| pECP61.5 | C4-HSL | |||
| pKDT17 | 3-oxo-C10- to 3-oxo-C12-HSL C10- to C12-HSL | |||
| pCF218, pMV26 | 3-oxo-C6- to 3-oxo-C12-HSL C4- to C12-HSL | |||
| pCF218, pCF372 | 3-oxo-C4- to 3-oxo-C12-HSL C5- to C10-HSL | |||
| pSB406 | 3-oxo-C4- to 3-oxo-C14-HSL C4- to C12-HSL | |||
| 3-oxo-C6- to 3-oxo-C8-HSL C4- to C8-HSL | Violacein | |||
| pAL105 | 3-oxo-C12-HSL | |||
| pAL101 | C4-HSL | |||
| pSB536 | C4-HSL | |||
| pSB403 | 3-oxo-C4- to 3-oxo-C14-HSL C4- to C12-HSL | |||
| pHV2001 | 3-oxo-C6- to 3-oxo-C8-HSL C6- to C8-HSL | |||
| pZLR4 | All 3-oxo-HSLs C6- to C14-HSL 3-OH-C6- to 3-OH-C10-HSL | |||
| pJZ384, pJZ410, pJZ372 | 3-oxo-C4- to 3-oxo-C18-HSL C4- to C18-HSL | |||
| pSF105, pSF107 | 3-OH-C6-HSL C6-HSL 3-OH-C8-HSL | |||
| pUCP18 | 3-oxo-C12-HSL | |||
| pMS402 | 3-oxo-C12-HSL | |||
| pUCGMAT1-4 | 3-oxo-C6-HSL | |||
| pREC-FF | 3-oxo-C6-HSL | |||
| M71LZ | 3-oxo-C10 to 3-oxo-C12-HSL | |||
| pAS-C8 | C8- to C10-HSL | |||
| pKR-C12 | 3-oxo-C10- to 3-oxo-C12-HSL | |||
| pJBA-132 | 3-oxo-C6-HSL C6- to C10-HSL |
Summary of quorum sensing peptide bio-sensor detection systems.
| 21-CSP (SGSLSTFFRLFNRSFTQALGK) | Not specified | β-galactosidase assay, Bacteriocin production, Transformation assay (Syvitski et al., | |
| Gelatinase Biosynthesis-Activating Pheromone (QNSPNIFGQWM, lacton linkage between S3 and M11) | Not specified | Bioluminescence (La Rosa et al., | |
| EntF (AGTKPQGKPASNLVECVFSLFKKCN) | 10 aM | Bacteriocin induction (Dunny et al., | |
| cAM373 (AIFILAS) | 50 pM | Microtiter dilution method (Mori et al., | |
| cAD1 (LFSLVLAG) | 50 pM | Microtiter dilution method (Mori et al., | |
| cCF10 (LVTLVFV) | 25 pM | Clumping induction assay (Mori et al., | |
| cPD1 (FLVMFLSG) | 40 pM | Clumping induction assay (Suzuki et al., | |
| cOB1 (VAVLVLGA) | Not specified | Clumping induction assay (Nakayama et al., | |
| iPD1 (ALILTLVS) | Not specified | Microtiter dilution method (Mori et al., | |
| iAD1 (LFVVTLVG) | Not specified | Microtiter dilution method (Mori et al., | |
| iAM373 (SIFTLVA) | 200 pM | Clumping induction assay (Nakayama et al., | |
| iCF10 (AITLIFI) | 10 nM | Inhibition of induced self-clumping (Nakayama et al., | |
| CSP (DSRIRMGFDFSKLFGK) | 0.2 nM | Biofilm formation assay (Petersen et al., | |
| CSP (DRRDPRGIIGIGKKLFG) | 200 ng/ml ≈ 105 nM | Transformation assay (Håvarstein et al., | |
| CSP (SQKGVYASQRSFVPSWFRKIFRN) | 200 ng/ml ≈ 72 nM | Transformation assay (Håvarstein et al., | |
| CSP (EMRISRIILDFLFLRKK) | 100 ng/ml ≈ 46 nM | Transformation assay (Pozzi et al., | |
| CSP (EMRLSKFFRDFILQRKK) | 100 ng/ml ≈ 45 nM | Transformation assay (Pozzi et al., | |
| EDF (NNWNN) | <100 ng/ml ≈ 150 nM | Colony forming units assay (Kolodkin-Gal et al., |
Summary of reported concentrations of quorum sensing molecules in different matrices.
| AI-2 | S. oralis 34 | 69–123 nM over 48 h (Rickard et al., | |
| 153–382 nM over 48 h (Rickard et al., | |||
| 124–197 nM over 48 h (Rickard et al., | |||
| 122–140 nM over 48 h (Rickard et al., | |||
| Saliva ( | HPLC-MS | 244–965 nM (mean = 526 nM) (Campagna et al., | |
| Saliva IBD patients ( | 1.67–2.29 μM (mean = 2.05 μM) (Raut et al., | ||
| Stool IBD patients ( | 1.57–3.59 μM (mean = 2.76 μM) (Raut et al., | ||
| Ileal washing IBD patients ( | 2.29 μM (Raut et al., | ||
| Saliva healthy volunteers ( | 0.998–2.07 μM (mean = 1.39 μM) (Raut et al., | ||
| 3-oxo-C12-HSL | Sputum samples ( | LC-MS | 20.24–6833.20 nM (Struss et al., |
| P. aeruginosa | LC-MS | Mean = 0.95 ± 0.68 μM (Struss et al., | |
| Sputum CF patients ( | LC-MS/MS | LLOQ (not specified)–410 nM (Barr et al., | |
| Sputum CF patients ( | pKDT17 with | 0.92–21.20 nM (mean = 5.04 nM) (Marchesan et al., | |
| HHQ | Sputum CF patients ( | LC-MS/MS | LLOQ (not specified)–1066 nM (Barr et al., |
| Plasma CF patients ( | LC-MS/MS | 0.01 nM (i.e., LLOQ)–2.744 nM (Barr et al., | |
| Urine CF patients ( | LC-MS/MS | 0.02 nM (i.e., LLOQ)–4.028 nM (Barr et al., | |
| NHQ | Sputum CF patients ( | LC-MS/MS | LLOQ (not specified)–1563 nM (Barr et al., |
| Plasma CF patients ( | LC-MS/MS | 0.01 nM (i.e., LLOQ)–0.222 nM (Barr et al., | |
| Urine CF patients ( | LC-MS/MS | 0.01 nM (i.e., LLOQ)–0.347 nM (Barr et al., | |
| HQNO | Sputum CF patients ( | LC-MS/MS | LLOQ (not specified)–780 nM (Barr et al., |
| Plasma CF patients ( | LC-MS/MS | 0.03 nM (i.e., LLOQ)–0.904 nM (Barr et al., | |
| Urine CF patients ( | LC-MS/MS | 0.03 nM (i.e., LLOQ)–12.511 nM (Barr et al., | |
| NQNO | Sputum CF patients ( | LC-MS/MS | LLOQ (not specified)–1075 nM (Barr et al., |
| Plasma CF patients ( | LC-MS/MS | 0.04 nM (i.e., LLOQ)–0.705 nM (Barr et al., | |
| Urine CF patients ( | LC-MS/MS | 0.05 nM (i.e., LLOQ)–2.067 nM (Barr et al., | |
| C7-PQS | Sputum CF patients ( | LC-MS/MS | LLOQ (not specified)–873 nM (Barr et al., |
| Plasma CF patients ( | LC-MS/MS | 0.1 nM (i.e., LLOQ)–0.571 nM (Barr et al., | |
| C9-PQS | Sputum CF patients ( | LC-MS/MS | LLOQ (not specified)–4302 nM (Barr et al., |
| C4-HSL | Sputum CF patients ( | LC-MS/MS | LLOQ (not specified)–145 nM (Barr et al., |
| Sputum CF patients ( | pECP61.5 with | 0.84–5.00 nM (mean = 1.04 nM) (Erickson et al., | |
| C10-HSL | LC-MS/MS | 260 nM (9% RSD) (Frommberger et al., | |
| C8-HSL | LC-MS/MS | 180 nM (12% RSD) (Frommberger et al., | |
Concentration of selected peptides in bacterial cell culture broths.
| cAM373 (AIFILAS) | 4.4 μg/16 L = 374 pM | HPLC-UV/VIS (Mori et al., | ||
| iPD1 (ALILTLVS) | 6.3 μg/20 L = 378 pM | HPLC-UV/VIS (Mori et al., | ||
| iCF10 (AITLIFI) | 15,360 pg/mL = 19,440 pM | Estimated via bio-assay via comparing with synthetic peptide (La Rosa et al., | ||
| cOB1 (VAVLVLGA) | 1.5 μg/15 L = 135 pM | HPLC-UV/VIS (Nakayama et al., | ||
| cAD1 (LFSLVLAG) | 200 μg/300 L = 814 pM | HPLC-UV/VIS (Mori et al., | ||
| iAD1 (LFVVTLVG) | 20 μg/20 L = 787 pM | HPLC-UV/VIS (Mori et al., | ||
| cCF10 (LVTLVFV) | 4.1 μg/60 L = 86 pM | HPLC-UV/VIS (concentration) FAB-MS (amino acid sequence confirmation) (Mori et al., | ||
| iAM373 (SIFTLVA) | 3 μg/8 L = 500 pM | HPLC-UV/VIS (Nakayama et al., |